<DOC>
	<DOCNO>NCT00924534</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics SLV337 patient type 2 diabetes</brief_summary>
	<brief_title>A Safety PK/PD Study SLV337 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria Type 2 diabetes , stable dose Metformin , HbA1c &gt; = 7 % , &lt; 9 % Exclusion Criteria Type 1 diabetes mellitus , Body Mass Index ( BMI ) &gt; 40.0 kg/m2 , evidence unstable cardiovascular disease , NYHA class I IV , ALT &gt; 1.5 time UNL , creatinine clearance &lt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>interventional</keyword>
	<keyword>placebo</keyword>
	<keyword>control</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>safety</keyword>
</DOC>